Add to ORKGThe results of preclinical and clinical studies using an HIV-1 Tat-based vaccines are described
The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov N...
The promising results obtained with the HIV-1 Tat-based vaccines in mice, monkeys and humans, a bett...
269-275Human immunodeficiency virus-1 (HIV-1) infection is characterized by chronic immune activatio...
The results of preclinical and clinical studies using an HIV-1 Tat-based vaccines are described
The HIV epidemic continues to represent one of the major problems worldwide, particularly in the Asi...
The HIV epidemic continues to represent one of the major problems worldwide, particularly in the Asi...
Over the last two decades most of the efforts in HIV vaccine development have been based on the use ...
Vaccination against human immunodeficiency virus (HIV)-1 infection requires candidate antigen(s) (Ag...
Vaccination against human immunodeficiency virus (HIV)-1 infection requires candidate antigen(s) (Ag...
OBJECTIVES: To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected...
Abstract. The human immunodeficiency virus Tat regulatory protein is essential for virus replication...
OBJECTIVES: To investigate which immune parameters, such as antibodies against HIV-1 specificities, ...
Abstract The human immunodeficiency virus type 1 (HIV-1) trans-activator of transcription protein Ta...
The promising results obtained with the HIV-1 Tat-based vaccines in mice, monkeys and humans, a bett...
The promising results obtained with the HIV-1 Tat-based vaccines in mice, monkeys and humans, a bett...
The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov N...
The promising results obtained with the HIV-1 Tat-based vaccines in mice, monkeys and humans, a bett...
269-275Human immunodeficiency virus-1 (HIV-1) infection is characterized by chronic immune activatio...
The results of preclinical and clinical studies using an HIV-1 Tat-based vaccines are described
The HIV epidemic continues to represent one of the major problems worldwide, particularly in the Asi...
The HIV epidemic continues to represent one of the major problems worldwide, particularly in the Asi...
Over the last two decades most of the efforts in HIV vaccine development have been based on the use ...
Vaccination against human immunodeficiency virus (HIV)-1 infection requires candidate antigen(s) (Ag...
Vaccination against human immunodeficiency virus (HIV)-1 infection requires candidate antigen(s) (Ag...
OBJECTIVES: To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected...
Abstract. The human immunodeficiency virus Tat regulatory protein is essential for virus replication...
OBJECTIVES: To investigate which immune parameters, such as antibodies against HIV-1 specificities, ...
Abstract The human immunodeficiency virus type 1 (HIV-1) trans-activator of transcription protein Ta...
The promising results obtained with the HIV-1 Tat-based vaccines in mice, monkeys and humans, a bett...
The promising results obtained with the HIV-1 Tat-based vaccines in mice, monkeys and humans, a bett...
The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov N...
The promising results obtained with the HIV-1 Tat-based vaccines in mice, monkeys and humans, a bett...
269-275Human immunodeficiency virus-1 (HIV-1) infection is characterized by chronic immune activatio...